Other Medicines
Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 37-46 out of 46 results
Neurology
Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment
Neurology
Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment
Neurology
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Other Medicines
IONIS-TMPRSS6-L Rx Data Presented at the DIA Oligonucleotide-Based Therapeutics Conference
Neurology
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Neurology
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Neurology
Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease
Neurology
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Neurology
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA